Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26716371 | 0.91 | HSD17B10 (0.49) | HSD17B10GNAI3GNAO1GNAI1EPHX2 | |
| SCHEMBL13746181 | 0.90 | GNAI3 (0.58) | HSD17B10GNAI3GNAO1GNAI1EPHX2 | |
| Hydrochloric Acid SCHEMBL21640745 | 0.86 | HSD17B10 (0.53) | HSD17B10GNAI3GNAO1GNAI1EPHX2 | |
| SCHEMBL21661360 | 0.81 | CHRNB2 (0.60) | HSD17B10GNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL2149339 | 0.81 | CHRNB2 (0.60) | HSD17B10GNAI3GNAO1GNAI1SMN1; SMN2 | |
| SCHEMBL7750667 | 0.81 | HSD17B10 (0.66) | HSD17B10EPHX2SMN1; SMN2GAARAB9A | |
| SCHEMBL16364960 | 0.80 | GNAI3 (0.49) | GNAI3GNAO1GNAI1SMN1; SMN2HTR2C | |
| SCHEMBL12574191 | 0.79 | GNAI3 (0.51) | GNAI3GNAO1GNAI1SMN1; SMN2HTR2C | |
| SCHEMBL3935665 | 0.79 | GNAI3 (0.51) | GNAI3GNAO1GNAI1SMN1; SMN2HTR2C | |
| SCHEMBL4635163 | 0.79 | GNAI3 (0.69) | GNAI3GNAO1GNAI1GAACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | claimed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | claimed |
| EP-1638933-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER INC. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | claimed |
| WO-2004110995-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | claimed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1638933-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
| WO-2004110995-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | HSD17B10 1430/4885GNAI3 1282/4885GNAO1 1172/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | HSD17B10 951/4885GNAI3 1455/4885GNAO1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.